Clinically Approved Antibiotics from 2010 to 2022

Erik Jung; Karl Gademann

doi:10.2533/chimia.2023.230

Clinically Approved Antibiotics from 2010 to 2022

Authors

Erik Jung University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057 Zurich https://orcid.org/0000-0002-6423-7619
Karl Gademann University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057 Zurich https://orcid.org/0000-0003-3053-0689

DOI:

https://doi.org/10.2533/chimia.2023.230

Keywords:

Antibiotics, Antimicrobial resistance, Natural products, Semisynthesis, Tuberculosis

Abstract

This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives (ceftaroline fosamil, cefiderocol, plazomicin, omadacycline, eravacycline, sarecycline, lefamulin, dalbavancin, oritavancin), and one natural product (fidaxomicin).